COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04683484 Nanogen Pharmaceutical Biotechnology JSC Nguyen T, SSRN, 2021 (a) Full text Full text Commentary Commentary |
Protein subunit |
Nanocovax 25 mcg Nanocovax 50 mcg |
Nanocovax 75 mcg |
RCTPhase 1 | Healthy HIV-negative and seronegative adults at a single center in Vietnam | N=60 |
Some concerns Details |
|
|
NCT04400838 AstraZeneca+University of Oxford Voysey M, Lancet, 2020 () COV002 Full text Commentary |
Non replicating viral vector |
ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (2·2 × 10¹? vp) /0.5mL (3.5 - 6.5 x 10¹?vp) ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (3.5 - 6.5 x 10¹?vp) |
Meningococcal group A, C, W-135, and Y conjugate vaccine 0.5mL, 2 x doses, Days 0/28 |
RCTPhase 2/3 | Healthy adults in 18 centres in the UK | N=10673 |
Some concerns Details |
|
|
ISRCTN89951424 AstraZeneca+University of Oxford Voysey M, Lancet, 2020 () COV003 Full text Commentary |
Non replicating viral vector |
ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (3.5 - 6.5 x 10^10vp) |
Meningococcal group A, C, W-135, and Y conjugate vaccine Day 0, saline 0.5mL (0.9% NaCl) Day 28 |
RCTPhase 3 | Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil | N=10002 |
Some concerns Details |
|